Clinical Significance of Lymphokine‐Activated Killer Activity in Childhood Acute Lymphoblastic Leukemia
作者:
Masao Kato,
期刊:
Pediatrics International
(WILEY Available online 1987)
卷期:
Volume 29,
issue 2
页码: 206-213
ISSN:1328-8067
年代: 1987
DOI:10.1111/j.1442-200X.1987.tb00034.x
出版商: Blackwell Publishing Ltd
关键词: Lymphokine‐activated killer;Childhood ALL;R‐IL2;Adoptive immunotherapy;Natural killer.
数据来源: WILEY
摘要:
AbstractLymphokine‐activated killer (LAK) activity was studied in 29 children with acute lymphoblastic leukemia (ALL). Peripheral blood lymphocytes of the patients and normal volunteers were cultured in the presence of recombinant‐interleukin 2 (R‐IL2) for five days, and assayed for their LAK activities by51Cr release assay using Raji cells as a target. At the time of onset, LAK activity was 4.3±2.6% (mean±SD, n=6) compared to the normal value. During remission LAK activity improved to 49.6±30.2% (n=16, p<0.01). After cessation of therapy LAK activity further improved to 97.3±21.2% (n=7, p<0.01). The conventional anti‐leukemic agents appeared to be suppressive for LAK activityin vitro.Of the patients in remission for more than one year, three with depressed LAK activity relapsed one to four months after the assay. Although it still remains undetermined whether the depression of LAK activity is responsible for the subsequent relapse, the application of adoptive immunotherapy using LAK and R‐IL2 is of clinical interest because it can be expected to enhance the activity of LAK. As compared with natural killer cell activity in childhood ALL, LAK activity showed a prompt improvement af
点击下载:
PDF
(476KB)
返 回